Title: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled 21 Day Treatment Study, Including an fMRI sub-study, to Evaluate the Effect of HT-3951 on Upper Extremity Motor Function Following Ischemic Stroke

Status: Enrollment closed as of December 2017

Sponsor: Dart NeuroScience, LLC (Commercial)

Site PI: Richard Zorowitz 

More Info: Enrolled subjects will have mild to moderately severe, unilateral upper extremity motor impairment, and will begin investigational treatment within 2-52 weeks post-stroke. Subjects will undergo standardized upper extremity rehabilitation with a therapist throughout the study.

Click here to view flyer

Click here to view brochure

Go to ClinicalTrials.gov for more details